Transcode Therapeutics Inc (RNAZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $22.35M
Last updated: Nov 17, 2026 at 11:02 AM ET
Transcode Therapeutics Inc (RNAZ) Earnings: Report Dates and Results
In the quarter ended Jun 30, 2026, Transcode Therapeutics reported EPS of -$7.17. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
RNAZ's next report is not on the earnings calendar yet.
Earnings History
Of the 14 quarters below that had an estimate, RNAZ beat 6, missed 7 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2025, when EPS landed 470.59% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$7.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2026 |
| Mar 31, 2026 | -$21.28 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 15, 2026 |
| Dec 31, 2025 | -$16.42 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 25, 2026 |
| Sep 30, 2025 | -$5.82 | -$1.02 | N/A | -470.59% | Miss | N/A | N/A | N/A | Nov 14, 2025 |
| Jun 30, 2025 | -$5.13 | -$1.64 | N/A | -212.80% | Miss | N/A | 1 | N/A | Aug 14, 2025 |
| Mar 31, 2025 | -$1,286.15 | -$89.88 | N/A | N/A | N/A | N/A | N/A | 0 up, 1 down | May 14, 2025 |
| Dec 31, 2024 | -$1,286.15 | -$89.88 | N/A | N/A | N/A | N/A | 1 | 1 up, 0 down | Mar 28, 2025 |
| Sep 30, 2024 | -$147.84 | -$452.76 | N/A | +67.35% | Beat | N/A | 1 | 1 up, 0 down | Nov 14, 2024 |
| Jun 30, 2024 | -$27,350.42 | -$21,436.81 | N/A | -27.59% | Miss | N/A | 1 | 0 up, 0 down | Aug 14, 2024 |
| Mar 31, 2024 | -$600.60 | -$25,872.02 | N/A | +97.68% | Beat | N/A | 1 | 0 up, 0 down | May 15, 2024 |
| Dec 31, 2023 | -$627.33 | -$356.40 | N/A | -76.02% | Miss | N/A | 1 | 0 up, 0 down | Mar 29, 2024 |
| Sep 30, 2023 | -$62,092.84 | -$55,440.03 | N/A | -12.00% | Miss | N/A | 1 | 0 up, 0 down | Nov 14, 2023 |
| Jun 30, 2023 | -$121,598.47 | -$125,294.48 | N/A | +2.95% | Beat | N/A | 1 | 0 up, 0 down | Aug 14, 2023 |
| Mar 31, 2023 | -$0.38 | -$0.38 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | May 15, 2023 |
| Dec 31, 2022 | -$288,288.17 | -$280,896.17 | N/A | -2.63% | Miss | N/A | 1 | 0 up, 0 down | Mar 30, 2023 |
| Sep 30, 2022 | -$243,936.15 | -$295,680.18 | N/A | +17.50% | Beat | N/A | 1 | 0 up, 0 down | Nov 14, 2022 |
| Jun 30, 2022 | -$266,112.16 | -$221,760.13 | N/A | -20.00% | Miss | -52178954.9% | N/A | 0 up, 0 down | Aug 15, 2022 |
| Mar 31, 2022 | -$0.22 | -$0.25 | N/A | +12.00% | Beat | N/A | N/A | 0 up, 0 down | May 16, 2022 |
| Dec 31, 2021 | -$170,016.10 | -$184,800.11 | N/A | +8.00% | Beat | N/A | 1 | 0 up, 0 down | Mar 31, 2022 |
| Sep 30, 2021 | -$0.20 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 15, 2021 |
| Jun 30, 2021 | $0.51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 9, 2021 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1,313.52, after -$29,385.01 the year before. It was -$170,015.79 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1,313.52 | N/A |
| Dec 31, 2024 | -$29,385.01 | N/A |
| Dec 31, 2023 | -$184,319.02 | N/A |
| Dec 31, 2022 | -$798,336.70 | N/A |
| Dec 31, 2021 | -$170,015.79 | N/A |
Frequently Asked Questions About RNAZ
How often does RNAZ beat earnings estimates?
Transcode Therapeutics beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -78.88%.
RNAZ pages: Overview, Earnings, Financials, Competitors